POST-VOID RESIDUAL URINE VOLUME IN WOMEN WITH OVERACTIVE BLADDER SYMPTOMS

2004 ◽  
Vol 172 (5) ◽  
pp. 1911-1914 ◽  
Author(s):  
MARK MILLEMAN ◽  
PETER LANGENSTROER ◽  
MICHAEL L. GURALNICK
Keyword(s):  
Overactive Bladder ◽  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Overactive Bladder Symptoms ◽  
Bladder Symptoms

scholarly journals Treatment of overactive bladder symptoms in women with Diunorm®: preliminary results report

2021 ◽  
Vol 9 (2) ◽  
pp. 100-110
Author(s):  
S. V. Shkodkin ◽  
M. V. Pokrovsky ◽  
S. S. Krasnyak ◽  
A. V. Polichuk ◽  
S. V. Chirkov ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Urine Volume ◽  
Evidence Base ◽  
Urine Flow ◽  
Residual Urine Volume ◽  
Female Population ◽  
Residual Urine ◽  
Awareness Tool ◽  
Bladder Symptoms ◽  
High Level

Introduction. Overactive bladder (OAB) with or without urgent incontinence tends to progress with age and occurs in both men and women. However, the frequency of occurrence in the female population averages about 25%.Purpose of the study. To assess the effectiveness and safety of the drug Diunorm® (in caps.) in the prevention and treatment of OAB in women.Materials and methods. The statistical analysis includes the results of a survey of 28 women with symptoms of OAB, whose average age was 35.3 years. The drug Diunorm® was used for treatment in dosage 400 mg QD for 90 days. Patients completed the Overactive Bladder Awareness Tool and a urination diary. Additionally, urinalysis, bacteriological examination of urine, uroflowmetry, bladder ultrasound and cystoscopy were performed.Results. All women throughout the study had negative urine cultures and no pyuria in urinalysis, which excluded an infectious etiology of urinary dysfunction. During therapy, a statistically significant decrease in irritative symptoms was recorded according to the Overactive Bladder Awareness Tool questionnaire. The sum of points after 1 and 3 mo decreased by 3.0 and 4.3 points, respectively (p < 0.05). Positive dynamics in terms of the points' sum was noted in 75%, in relation to nocturia in 82% of patients (p < 0.01). The average urination rate increased from 13.3 ± 0.7 ml/s to 15.1 ± 0.7 ml/s and 15.4 ± 0.5 ml/s after 1.5 and 3 months, respectively (p < 0,0001). A similar trend was observed for maximum urine flow and residual urine volume. The maximum urine flow when taking Diunorm® increased from 15.9 ± 0.6 ml/s to 17.4 ± 0.5 ml/s and 18.1 ± 0.4 ml/s (p < 0.001). Residual urine volume decreased throughout the study. When included in the study, after 1,5 and 3 mo, this indicator was 19.9 ± 1.4; 12.2 ± 1.6 and 6.4 ± 1.1 ml, respectively (p < 0.001).Conclusion. Diunorm® can become a worthy alternative to traditional first-line OAB therapy. Comparative studies are required to obtain a high-level evidence base.

scholarly journals Whether a good uroflow rate could guarantee a low post-void residual urine volume in men with overactive bladder?

2016 ◽  
Vol 27 (2) ◽  
pp. S49
Author(s):  
Kuan-Jung Lin ◽  
Chih-Chieh Lin ◽  
Alex Tong-Long Lin ◽  
Kuang-Kuo Chen
Keyword(s):  
Overactive Bladder ◽  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine

scholarly journals The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Naoya Masumori ◽  
Shintaro Miyamoto ◽  
Taiji Tsukamoto ◽  
Seiji Furuya ◽  
Akihiko Iwasawa ◽  
...  
Keyword(s):  
Adverse Event ◽  
Overactive Bladder ◽  
Urine Volume ◽  
Previous Treatment ◽  
Efficacy And Safety ◽  
Anticholinergic Agents ◽  
Residual Urine Volume ◽  
Frequent Adverse Event ◽  
Postvoid Residual Urine ◽  
Bladder Symptoms

Objectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin.Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB symptom score (OABSS)) even after at least 4-week treatment using solifenacin, tolterodine or imidafenacin were enrolled. Propiverine 20 mg/day was administered for 12 weeks to 70 patients who desired the further improvement of OAB symptoms and 3 who had intolerable adverse events of previous drugs. The OABSS and postvoid residual urine volume (PVR) were determined before and at 4 and 12 weeks of treatment.Results. Of 73 patients enrolled (29 males and 44 females, median age 71 years), 52 completed the protocol treatment. The OABSS was significantly improved by propiverine treatment (9.0 at baseline, 6.2 at 4 weeks, 6.3 at 12 weeks (P<0.001)). The scores of OAB symptoms (nighttime frequency, urgency and urge incontinence) except daytime frequency also improved significantly. No increase in PVR was observed. The most frequent adverse event was dry mouth (13.7%), followed by constipation (6.8%).Conclusions. Propiverine is useful to improve OAB for patients who poorly respond to solifenacin, tolterodine or imidafenacin.

Sign in / Sign up

Export Citation Format

Share Document